HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR

Abstract: A human peroxisome proliferation activated receptor gene is purified from the environment in which it naturally occurs, and preferably provided within an expression vector.

Description: DESCRIPTION Human Peroxisome Proliferator Activated Receptor Cross Reference to Related Application This application is a continuation-in-part of Application Docket No. 202/041, titled "Human Peroxisome Proliferator Activated Receptor," filed October 22, 1993, by Mukherjee, the disclosure of which is incorporated herein by reference. Field of the Invention This invention relates to the cloning and uses of a human peroxisome proliferator activated receptor. Background of the Invention A peroxisome proliferator is an agent that induces peroxisomal proliferation. Peroxisome proliferators are a diverse group of chemicals which include unsaturated fatty acids, hypolipidemic drugs, herbicides, leukotriene antagonists, and plasticizers (for a review, see Green, S., 43 Biochem. Pharmacol. 393-400, 1992). Hypolipidemic drugs such as clofibrates have been found to lower triglycerides and cholesterol levels in plasma and to be beneficial in the prevention of ischaemic heart disease in individuals with elevated levels of cholesterol (Havel, R.J. and Kane, J.P., 13 Ann. Rev. Pharmac. 287-308, 1973). Therapeutic use of such drugs, however, is questioned because clofibrates are carcinogens in rats. Peroxisome proliferator activated receptor (PPAR) is a member of the steroid receptor family. It is activated by peroxisome proliferators. Issemann and Green, 347 Nature 645, 1990, cloned a mouse peroxisome proliferator activated receptor (mPPAR) gene from a mouse liver comple¬ mentary DNA (cDNA) library. Gδttlicher et al., 89 Proc. Nat. Acad. Sci. USA 4653-4657, 1992, cloned a rat peroxisome proliferator activated receptor (rPPAR) gene from a rat liver cDNA library. PPARs from mouse and rat share 97% homology in amino acid sequence and a particularly well-conserved putative ligand-binding domain. Three members of the Xenopus nuclear hormone receptor superfa ily have also been found to be structurally and functionally related to the mPPAR (Dreyer et al., 68 Cell 879-887, 1992) . Schmidt et al., 6 Molecular Endocrinology 1634-1641, 1992, cloned a steroid hormone receptor gene, NUCl. from a human osteosarcoma cell cDNA library. The homology between amino acid sequence of NUCl and that of the mouse PPAR is only 62%. Thus, although it is clear that NUCl is a member of the PPAR receptor group, it remains to be determined whether NUCl is the human homolog of the mouse PPAR or a new member of the PPAR family. Sher et al. , 32 Biochemistry 5598-5604, 1993, cloned a human PPAR gene from a human liver cDNA library. This clone has 85% nucleotide sequence homology and 91% amino acid sequence homology with the mPPAR clone. Summary of the Invention The present invention relates to the cloning of a human PPAR gene, hPPARl. The protein encoded by hPPARl has 92% homology with the mouse PPAR. It is different from the human PPAR cloned by Sher et al., supra, at two locations in the amino acid sequence, i.e., amino acids 268 and 296. The hPPARl clone can be used for the expression of large amounts of hPPARl. This human PPAR clone is also useful for screening compounds for improved pharmacological profiles for the treatment of hyperlipidemia with higher potency, efficacy, and fewer side effects. Specifically, the human PPAR clone can be used to screen for compounds active as primary endogenous inducers of the human PPAR. In addition, it is useful for establishing the tissue specific expression pattern of human PPAR. For example, a Northern blot can be used to reveal tissue specific expression of the gene to aid treatment of diseases such as atherosclerosis. Thus, in a first aspect, the invention features a purified nucleic acid encoding a human PPAR with the nucleotide base sequence shown in Figure 1, and given as SEQ ID NO. 1. By purified nucleic acid is meant that the nucleic acid is separated from its natural environment and from other nucleic acids. In a second aspect, the present invention features a vector containing the human PPAR gene. This vector may be used for multiplication of the human PPAR gene or expression of the human PPAR gene. In a preferred embodiment, the vector is an expression vector. In one example, the expression vector is used to make a recombinant human PPAR nucleic acid, which can be used as a specific probe for DNA or RNA complementary to the human PPAR sequence. In another example, the expression vector is used to express human recombinant PPAR protein. By vector is meant a plasmid or viral DNA molecule into which either a cDNA or a genomic DNA sequence is inserted. By expression vector is meant a vector that directs protein synthesis from a promoter. In a preferred embodiment, either vector pBacPAKS (Clontech) or vector pBacPAK9 (Clontech) is used to express the human PPAR in insect cells. In another preferred embodiment, vector pYES2 (Invitrogen) is used to express the human PPAR in yeast cells. In yet another preferred embodiment, pBKCMV (Stratagene) is used to express the human PPAR in mammalian cells. By recombinant human PPAR is meant a non-naturally expressed human PPAR. Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. Description of the Preferred Embodiments Drawings Figure 1 is the nucleotide and amino acid sequence of hPPARl; and Figure 2 is a comparison of the amino acid sequences of hPPARl and the mouse PPAR. What follows is an example of the cloning of a human PPAR. Those of ordinary skill in the art will recognize that equivalent procedures can be readily used to isolate human PPAR from cDNA libraries or genomic libraries of other tissues than that exemplified below, namely the liver. In general, the cloning of the human PPAR involved probing a human liver cell cDNA library with a labeled EcoRI-Bglll fragment (nucleotides 450-909) of the rat PPAR (459 bases) . The sequence of the probe is shown in Gottlicher et al. supra. The recipes for buffers, mediums, and solutions in the following examples are given in J. Sambrook, E. F. Fritsch, and T. Maniatis, Molecular Cloning; A Laboratory Manual, 2 Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Example 1; Cloning of a human PPAR A human PPAR subtype, hPPARl, was cloned from a human liver 5'-stretch cDNA library (Clontech #HL1115a) in lambda gtlO phages. C600-Hfl coli (Clontech) was grown overnight in LB broth supplemented with 0.2% maltose. A required amount of phage (corresponding to 2 million plaques) was mixed with 200 microliters of 10 mM MgCl_/10 mM CaCl, and 1.5 milliliters of the overnight C600-Hfl coli and incubated at 37°C for 30 minutes. Soft LB agarose was added at 48°C, mixed and poured onto prewarmed 22x22 cm rectangular LB agar plates and incubated overnight at 37°C. Plaque lifts were performed by chilling the plates at 4°C to harden the top agarose and prevent it from peeling, marking a nylon or nitrocellulose filter on the surface contacting the plaques, laying the filter on the surface without trapped air bubbles, and leaving it for about a minute. A number of asymmetric dots were inserted with Indian ink with a syringe and needle so that the ink soaked into the agar. The sheets were then peeled gently away, and laid plaque side up on two sheets of Whattman 3MM soaked in denaturing solution, and left for about 2 minutes. The sheets were then peeled away and immersed in a standard neutralizing solution for 5 minutes, immersed in 5X SSC, air dried, and baked at 80°C under vacuum, for 2 hours. The filters were prehybridized in 40% formamide, 5X SSC, 0.1 % SDS, IX Denhardt, and 100 ng/ml denatured salmon sperm DNA at 37°-42°C for 1 hour. Labeled DNA probe (1 million cpm/ml) was denatured by heating at 100°C for 10 minutes, chilled, and then added to the prehybridization solution, and hybridized at 37°-42°C overnight. The filters were washed in 2X SSC and, 0.1% SDS at 42°C or higher temperature. Positive plaques were identified and purified by rescreening two more times. The probe was labeled by nick-translation. Phage stocks were made by isolating and removing a well separated plaque with the narrow end of an autoclaved Pasteur pipette, immersing it in 1 ml of standard SM buffer, and adding a drop of chloroform. This was left for a few hours at room temperature (20°C-24°C) or overnight at 4°C, vortexed, and centrif ged. The cDNA insert was amplified by polymerase chain reactions (PCR) . 20 microliters of phage stock was used in 100 microliters of standard PCR reaction buffer, by adding all components except Polymerase. This mixture was heated to 99°C, and Vent DNA polymerase (Biolabs) was added to start the PCR cycles. The PCR conditions were 95°C 1 minute, 72°C 1 minute, 72°C 3 minutes (l minute per kilobase) for 30 cycles, 72°C 5 minutes, and kept at 4°C till further utilized. The applicant isolated a clone from the cDNA library using an EcoRI-Bglll fragment (nucleotides 450-909) of the rat PPAR (459 bases) as a probe and the hybridization conditions provided above. This clone was purified and its sequence defined. This sequence is shown in Figure 1, and as SEQ. ID. NO. 1. Figure 2 is a comparison of mPPAR and hPPARl amino acid sequences with those amino acids having identity between the two sequences enclosed in blocks. Example 2: Northern blot analysis A human multiple tissue Northern blot was purchased from Clontech. ' Screening was done following the manufacturer's protocol. The blot was prehybridized in 5X SSPE, 10X Denhardt's solution, lOOμg/ml of freshly denatured salmon sperm DNA, 50% formamide and 2% SDS for 3 hours at 42°C. DNA from the EcoRl site at position 1025 of the coding region to the end of the cloned gene was used as probe (see Figure 1) . This DNA was labeled by random priming, boiled and added at a concentration of 1 million cpm/ml of prehybridization solution. Hybridization was carried out for 13 hours at 42°C. The blot was then washed in 2X SSC, 0.05% SDS at room temperature followed by two washes in 0.1X SSC, 0.1% SDS at 50°C and exposed to X-ray film. A specific band of about 10 kilobase was observed in all tissues except the brain. Maximal expression was observed in skeletal muscle, followed by heart, placenta, pancreas, liver, kidney, and lung. The expression of hPPARl gene is therefore observed in tissues known to express PPARs in other species. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: LIGAND PHARMACEUTICALS, INC. (B) STREET: 9393 Towne Centre Drive (C) CITY: San Diego (D) STATE: California (E) COUNTRY: United States of America (F) POSTAL CODE (ZIP) : 92121 (G) TELEPHONE: (619) 535-3900 (H) TELEFAX: (619) 535-3906 (ii) TITLE OF INVENTION: HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (iii) NUMBER OF SEQUENCES: 3 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb (B) COMPUTER: IBM compatible (C) OPERATING SYSTEM: IBM P.C. DOS (Version 5.0) (D) SOFTWARE: WordPerfect (Version 5.1) (v) CURRENT APPLICATION DATA: APPLICATION NUMBER: To Be Assigned (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/141,500 (B) FILING DATE: 22-OCT-1993 (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/143,215 (B) FILING DATE: 26-OCT-1993 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1407 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 1: ATG GTG GAC ACG GAA AGC CCA CTC TGC CCC CTC TCC CCA 39 Met Val Asp Thr Glu Ser Pro Leu Cys Pro Leu Ser Pro 5 10 CTC GAG GCC GGC GAT CTA GAG AGC CCG TTA TCT GAA GAG 78 Leu Glu Ala Gly Asp Leu Glu Ser Pro Leu Ser Glu Glu 15 20 25 TTC CTG CAA GAA ATG GGA AAC ATC CAA GAG ATT TCG CAA 117 Phe Leu Gin Glu Met Gly Asn lie Gin Glu lie Ser Gin 30 35 TCC ATC GGC GAG GAT AGT TCT GGA AGC TTT GGC TTT ACG 156 Ser lie Gly Glu Asp Ser Ser Gly Ser Phe Gly Phe Thr 40 45 50 GAA TAC CAG TAT TTA GGA AGC TGT CCT GGC TCA GAT GGC 195 Glu Tyr Gin Tyr Leu Gly Ser Cys Pro Gly Ser Asp Gly 55 60 65 TCG GTC ATC ACG GAC ACG CTT TCA CCA GCT TCG AGC CCC 234 Ser Val lie Thr Asp Thr Leu Ser Pro Ala Ser Ser Pro 70 75 TCC TCG GTG ACT TAT CCT GTG GTC CCC GGC AGC GTG GAC 273 Ser Ser Val Thr Tyr Pro Val Val Pro Gly Ser Val Asp 80 85 90 GAG TCT CCC AGT GGA GCA TTG AAC ATC GAA TGT AGA ATC 312 Glu Ser Pro Ser Gly Ala Leu Asn lie Glu Cys Arg lie 95 100 TGC GGG GAC AAG GCC TCA GGC TAT CAT TAC GGA GTC CAC 351 Cys Gly Asp Lys Ala Ser Gly Tyr His Tyr Gly Val His 105 110 115 GCG TGT GAA GGC TGC AAG GGC TTC TTT CGG CGA ACG ATT 390 Ala Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Thr lie 120 125 130 CGA CTC AAG CTG GTG TAT GAC AAG TGC GAC CGC AGC TGC 429 Arg Leu Lys Leu Val Tyr Asp Lys Cys Asp Arg Ser Cys 135 140 AAG ATC CAG AAA AAG AAC AGT TTC AAA TGC CAG TAT TGT 468 Lys lie Gin Lys Lys Asn Arg Asn Lys Cys Gin Tyr Cys 145 150 155 CGA TTT CAC AAG TGC CTT TCT GTC GGG ATG TCA CAC AAC 507 Arg Phe His Lys Cys Leu Ser Val Gly Met Ser His Asn 160 165 GJ ATT CGT TTT GGA CGA ATG CCA AGA TCT GAG AAA GCA 546 Ala lie Arg Phe Gly Arg Met Pro Arg Ser Glu Lys Ala 170 175 180 AAA CTG AAA GCA GAA ATT CTT ACC TGT GAA CAT GAC ATA 585 Lys Leu Lys Ala Glu lie Leu Thr Cys Glu His Asp lie 185 190 195 GAA GAT TCT GAA ACT GCA GAT CTC AAA TCT CTG GCC AAG 624 Glu Asp Ser Glu Thr Ala Asp Leu Lys Ser Leu Ala Lys 200 205 AGA ATC TAC GAG GCC TAC TTG AAG AAC TTC AAC ATG AAC 663 Arg lie Tyr Glu Ala Tyr Leu Lys Asn Phe Asn Met Asn 210 215 220 AAG GTC AAA GCC CGG GTC ATC CTC TCA GGA AAG GCC AGT 702 Lys Val Lys Ala Arg Val lie Leu Ser Gly Lys Ala Ser 225 230 AAC AAT CCA CCT TTT GTC ATA CAT GAT ATG GAG ACA CTG 741 Asn Asn Pro Pro Phe Val lie His Asp Met Glu Thr Leu 235 240 245 TGT ATG GCT GAG AAG ACG CTG GTG GCC AAG CTG GTG GCC 780 Cys Met Ala Glu Lys Thr Leu Val Ala Lys Leu Val Ala 250 255 260 AAT GGC ATC CAG AAC AAG GAG GCG GAG GTC CGC ATC TTT 819 Asn Gly lie Gin Asn Lys Glu Ala Glu Val Arg lie Phe 265 270 CAC TCG TGC CAG TGC ACG TCA GTG GTG ACC GTC ACG GAG 858 His Cys Cys Gin Cys Thr Ser Val Glu Thr Val Thr Glu 275 280 285 CTC ACG GAA TTC GCC AAG GCC ATC CCA GGC TTC GCA AAC 897 Leu Thr Glu Phe Ala Lys Ala lie Pro Gly Phe Ala Asn 290 295 TTG GAC CTG AAC GAT CAA GTG ACA TTG CTA AAA TAC GGA 936 Leu Asp Leu Asn Asp Gin Val Thr Leu Leu Lys Tyr Gly 300 305 ' 310 GTT TAT GAG GCC ATA TTC GCC ATG CTG TCT TCT GTG ATG 975 Val Tyr Glu Ala lie Phe Ala Met Leu Ser Ser Val Met 315 320 325 AAC AAA GAC GGG ATG CTG GTA GCG TAT GGA AAT GGG TTT 1014 Asn Lys Asp Gly Met Leu Val Ala Tyr Gly Asn Gly Phe 330 335 ATA ACT CGT GAA TTC CTA AAA AGC CTA AGG AAA CCG TTC 1053 lie Thr Arg Glu Phe Leu Lys Ser Leu Arg Lys Pro Phe 340 345 350 TGT GAT ATC ATG GAA CCC AAG TTT GAT TTT GCC ATG AAG 1092 Cys Asp lie Met Glu Pro Lys Phe Asp Phe Ala Met Lys 355 360 TTC AAT GCA CTG GAA CTG GAT GAC AGT GAT ATC TCC CTT 1131 Phe Asn Ala Leu Glu Leu Asp Asp Ser Asp lie Ser Leu 365 370 375 TTT GTG GCT GCT ATC ATT TGC TGT GGA GAT CGT CCT GGC 1170 Phe Val Ala Ala lie lie Cys Cys Gly Asp Arg Pro Gly 380 385 390 CTT CTA AAC GTA GGA CAC ATT GAA AAA ATG CAG GAG GGT 1209 Leu Leu Asn Val Gly His lie Glu Lys Met Gin Glu Gly 395 400 ATT GTA CAT GTG CTC AGA CTC CAC CTG CAG AGC AAC CAC 1248 lie Val His Val Leu Arg Leu His Leu Gin Ser Asn His 405 410 415 CCG GAC GAT ATC TTT CTC TTC CCA AAA CTT CTT CAA AAA 1287 Pro Asp Asp lie Phe Leu Phe Pro Lys Leu Leu Gin Lys 420 425 ATG GCA GAC CTC CGG CAG CTG GTG ACG GAG CAT GCG CAG 1326 Met Ala Asp Leu Arg Gin Leu Val Thr Glu His Ala Gin 430 435 440 CTG GTG CAG ATC ATC AAG AAG ACG GAG TCG GAT CGT GCG 1365 Leu Val Gin lie lie Lys Lys Thr Glu Ser Asp Ala Ala 445 450 455 CTG CAC CCG CTA CTG CAG GAG ATC TAC AGG GAC ATG TAC 1404 Leu His Pro Leu Leu Gin Glu lie Tyr Arg Asp Met Tyr 460 465 TGA 1407 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 468 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 2 Met Val Asp Thr Glu Ser Pro Leu Cys Pro Leu Ser Pro 5 10 Leu Glu Ala Gly Asp Leu Glu Ser Pro Leu Ser Glu Glu 15 20 25 Phe Leu Gin Glu Met Gly Asn lie Gin Glu lie Ser Gin 30 35 Ser lie Gly Glu Asp Ser Ser Gly Ser Phe Gly Phe Thr 40 45 50 Glu Tyr Gin Tyr Leu Gly Ser Cys Pro Gly Ser Asp Gly 55 60 65 Ser Val lie Thr Asp Thr Leu Ser Pro Ala Ser Ser Pro 70 75 Ser Ser Val Thr Tyr Pro Val Val Pro Gly Ser Val Asp 80 85 90 Glu Ser Pro Ser Gly Ala Leu Asn lie Glu Cys Arg lie 95 100 Cys Gly Asp Lys Ala Ser Gly Tyr His Tyr Gly Val His 105 110 115 Ala Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Thr lie 120 125 130 Arg Leu Lys Leu Val Tyr Asp Lys Cys Asp Arg Ser Cys 135 140 Lys lie Gin Lys Lys Asn Arg Asn Lys Cys Gin Tyr Cys 145 150 155 Arg Phe His Lys Cys Leu Ser Val Gly Met Ser His Asn 160 165 Ala lie Arg Phe Gly Arg Met Pro Arg Ser Glu Lys Ala 170 175 180 Lys Leu Lys Ala Glu lie Leu Thr Cys Glu His Asp lie 185 190 195 Glu Asp Ser Glu Thr Ala Asp Leu Lys Ser Leu Ala Lys 200 205 Arg lie Tyr Glu Ala Tyr Leu Lys Asn Phe Asn Met Asn 210 215 220 Lys Val Lys Ala Arg Val lie Leu Ser Gly Lys Ala Ser 225 230 Asn Asn Pro Pro Phe Val lie His Asp Met Glu Thr Leu 235 240 245 Cys Met Ala Glu Lys Thr Leu Val Ala Lys Leu Val Ala 250 255 260 Asn Gly lie Gin Asn Lys Glu Ala Glu Val Arg lie Phe 265 270 His Cys Cys Gin Cys Thr Ser Val Glu Thr Val Thr Glu 275 280 285 Leu Thr Glu Phe Ala Lys Ala lie Pro Gly Phe Ala Asn 290 295 Leu Asp Leu Asn Asp Gin Val Thr Leu Leu Lys Tyr Gly 300 305 310 Val Tyr Glu Ala lie Phe Ala Met Leu Ser Ser Val Met 315 320 325 Asn Lys Asp Gly Met Leu Val Ala Tyr Gly Asn Gly Phe 330 335 lie Thr Arg Glu Phe Leu Lys Ser Leu Arg Lys Pro Phe 340 345 350 Cys Asp lie Met Glu Pro Lys Phe Asp Phe Ala Met Lys 355 360 Phe Asn Ala Leu Glu Leu Asp Asp Ser Asp lie Ser Leu 365 370 375 Phe Val Ala Ala lie lie Cys Cys Gly Asp Arg Pro Gly 380 385 390 Leu Leu Asn Val Gly His lie Glu Lys Met Gin Glu Gly 395 400 lie Val His Val Leu Arg Leu His Leu Gin Ser Asn His 405 410 415 Pro Asp Asp lie Phe Leu Phe Pro Lys Leu Leu Gin Lys 420 425 Met Ala Asp Leu Arg Gin Leu Val Thr Glu His Ala Gin 430 435 440 Leu Val Gin lie lie Lys Lys Thr Glu Ser Asp Ala Ala 445 450 455 Leu His Pro Leu Leu Gin Glu lie Tyr Arg Asp Met Tyr 460 465 468 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 468 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 3: Met Val Asp Thr Glu Ser Pro lie Cvs Pro Leu Ser Pro 5 10 Leu Glu Ala Asp Asp Leu Glu Ser Pro Leu Ser Glu Glu 15 20 25 Phe Leu Gin Glu Met Gly Asn lie Gin Glu lie Ser Gin 30 35 Ser lie Gly Glu Glu Ser Ser Gly Ser Phe Gly Phe Ala 40 45 50 Asp Tyr Gin Tyr Leu Gly Ser Cys Pro Gly Ser Glu Gly 55 60 65 Ser Val lie Thr Asp Thr Leu Ser Pro Arg Ser Ser Pro 70 75 Ser Ser Val Ser Cys Pro Val lie Pro Ala Ser Thr Asp 80 85 90 Glu Ser Pro Gly Ser Ala Leu Asn lie Glu Cys Arg lie 95 100 Cys Gly Asp Lys Ala Ser Gly Tyr His Tyr Gly Val His 105 110 115 Ala Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Thr lie 120 125 130 Arg Leu Lys Leu Val Tyr Asp Lys Cys Asp Arg Ser Cys 135 140 Lys lie Gin Lys Lys Asn Arg Asn Lys Cys Gin Tyr Cys 145 150 155 Arg Phe His Lys Cys Leu Ser Val Gly Met Ser His Asn 160 165 Ala lie Arg Phe Gly Arg Met Pro Arg Ser Glu Lys Ala 170 175 180 Lys Leu Lys Ala Glu lie Leu Thr Cys Glu His Asp Leu 185 190 195 Lys Asp Ser Glu Thr Ala Asp Leu Lys Ser Leu Gly Lys 200 205 Arg lie His Glu Ala Tyr Leu Lys Asn Phe Asn Met Asn 210 215 220 Lys Val Lys Ala Arg Val lie Leu Ala Gly Lys Thr Ser 225 230 Asn Asn Pro Pro Phe Val lie His Asp Met Glu Thr Leu 235 240 245 Cys Met Ala Glu Lys Thr Leu Val Ala Lys Met Val Ala 250 255 260 Asn Gly Val Glu Asp Lys Glu Ala Glu Val Arg Phe Phe 265 270 His Cys Cys Gin Cys Met Ser Val Glu Thr Val Thr Glu 275 280 285 Leu Thr Glu Phe Ala Lys Ala lie Pro Gly Phe Ala Asn 290 295 Leu Asp Leu Asn Asp Gin Val Thr Leu Leu Lys Tyr Gly 300 305 310 Val Tyr Glu Ala lie Phe Thr Met Leu Ser Ser Leu Met 315 320 325 Asn Lys Asp Gly Met Leu lie Ala Tyr Gly Asn Gly Phe 330 335 lie Thr Arg Glu Phe Leu Lys Asn Leu Arg Lys Pro Phe 340 345 350 Cys Asp lie Met Glu Pro Lys Phe Asp Phe Ala Met Lys 355 360 Phe Asn Ala Leu Glu Leu Asp Asp Ser Asp lie Ser Leu 365 370 375 Phe Val Ala Ala lie lie Cys Cys Gly Asp Arg Pro Gly 380 385 390 Leu Leu Asn lie Gly Tyr lie Glu Lys Leu Gin Glu Gly 395 400 lie Val His Val Leu Lys Leu His Leu Gin Ser Asn His 405 410 415 Pro Asp Asp Thr Phe Leu Phe Pro Lys Leu Leu Gin Lys 420 425 Met Val Asp Leu Arg Gin Leu Val Thr Glu His Ala Gin 430 435 440 Leu Val Gin Val lie Lys Lys Thr Glu Ser Asp Ala Ala 445 450 455 Leu His Pro Leu Leu Gin Glu lie Tyr Arg Asp Met Tyr 460 465 468

Claims: What is claimed is: 1. Purified nucleic acid comprising the nucleotide sequence shown in SEQ ID NO. 1. 2. A vector comprising said nucleic acid of claim 1. 3. Recombinant PPAR expressed from said nucleic acid of claim 1.

Inventors: MUKHERJEE RANJAN, MUKHERJEE, RANJAN
Applicants: LIGAND PHARM INC, LIGAND PHARMACEUTICALS, INC.
Application year: 1994
Main classification: C12N15
IPC codes: C07H21, C07K14, C12N15, C12P21